A set of five reverse transcriptase mutations, which include Q151M, is known to confer multidideoxynucleoside resistance (MDR) in human immunodeficiency virus type 1 (HIV-1). MDR mutations were found in 6 (17%) HIV-1 isolates from 36 patients, most of whom were receiving longterm combination therapy. Q151M was among the first of the substitutions to appear. Additional substitutions were observed, although none were common among all 6 patients. Certain zidovudinerelated mutations were not observed together with the MDR mutations, indicating possible enzymatic constraint. During chemotherapy, the HIV-1 RNA levels in the 6 patients initially decreased and then rose. Initially, CD4 cell counts also responded favorably but were near or below baseline beyond 40 months of therapy. Such loss of clinical benefits appeared to coincide with the appearance of the MDR mutations. A common background genotype was not observed among HIV-1 isolates with or without MDR.
Human immunodeficiency virus type 1 (HIV-1) develops carrying combined mutations have comparable catalytic efficiency (k cat /K m ) as examined using homopolymeric DNA and resistance against virtually any currently available therapeutic reverse transcriptase (RT) and protease inhibitors [1 -6] . In an heteropolymeric RNA templates [14, 15] . Furthermore, it has been demonstrated that, as assessed in vitro in the presence attempt to delay or block the development of drug-resistant HIV-1 variants and alleviate drug toxicities, multidrug antiviral of zidovudine or didanosine, HIV-1 with the five amino acid substitutions has a replication advantage over that of HIV-1, therapy has been widely used [7, 8] . However, a set of five mutations in the pol gene (including Ala 62jVal substitution with fewer MDR-associated amino acid substitutions [16] . The frequency of the emergence of these MDR-associated [A62V], V75I, F77L, F116Y, and Q151M) has been identified in HIV-1 isolates from patients receiving long-term combinaamino acid substitutions appears to be relatively low, although many of the patients examined to date have received combination chemotherapy with zidovudine plus zalcitabine or zidovudine plus didanosine. This set of mutations confers onto HIVtion chemotherapy for £2 years [11, 17] . It is conceivable that the frequency may increase in the future, considering that 1 reduced sensitivity to multiple dideoxynucleosides [5, 9 -13] . Detailed studies on sequentially obtained clinical HIV-1 longer periods of combination chemotherapy consisting of multiple RT inhibitors with or without protease inhibitor(s) will isolates have shown that these mutations develop in a relatively ordered manner and that a stepwise increase in resistance is be used more frequently. Therefore, in this study, we examined the RT-encoding gene of HIV-1 isolates from 36 patients, most associated with the accumulated mutations.
The alteration of RT's substrate recognition, caused by the of whom were receiving combination therapy with zidovudine plus didanosine for ú36 months. We also examined whether five mutations, appears to account for the viral multi-dideoxynucleoside resistance (MDR) [14, 15] . Indeed, a marked difthe emergence of the MDR-associated amino acid substitutions was related to immunologic, virologic, and clinical manifestaference has been noted in inhibition constants (K i ; e.g., the K i of a mutant RT carrying the five mutations is 62-fold higher tions. for AZTTP than is the K i of wild-type RT [RT wt ]); however, steady-state kinetic studies have shown that RT wt and RTs
Materials and Methods
Patients. All patients were enrolled in research protocols of the National Cancer Institute and were seen in the outpatient de-JID 1998;177 (June) Multi-Dideoxynucleoside-Resistant HIV-1 nosine monotherapy followed by zidovudine monotherapy, and the
Results
remaining patient received consecutive monotherapies of didanosine, zidovudine, lamivudine, and zalcitabine. cluded 12 months prior to commencement of didanosine. had declined by 67%, 89%, and 60% for patients B, C, and F, Second-round PCR products were first purified with PCR Select respectively.
Development of MDR mutations among patients receiving Preparation of peripheral blood mononuclear cells (PBMC
III columns (5 Primej3 Prime, Boulder, CO) and directly seAll patients (except patient F, whose pretherapy samples quenced using both M13-forward and M13-reverse dye-labeled were not available) had a mean log decrease of 1.17 (range, primers on an automated DNA sequencer (model 373; PerkinElmer, Foster City, CA). Following electrophoresis, sample files 0.10 -2.33) relative to baseline in HIV-1 RNA levels within 1 were processed by use of Factura software (Perkin-Elmer). Heteromonth of therapy. However, the viremia levels also rose as zygous base sequences were identified when electropherograms therapy ensued, and at the completion of study, the levels were showed a minor peak at §50% of the major peak. Sample files close to baseline RNA levels in all patients, ranging from a were aligned by use of AutoAssembler software (Perkin-Elmer) 0.62 log decrease to a 1.52 log rise above baseline (mean, 0.08 to generate a deduced nucleotide sequence, which was translated log increase; figure 1). As mentioned above, baseline HIV-1 to yield the amino acid sequence.
RNA was not determined for patient F; however, it rose from Molecular cloning. Several HIV-1 isolates were subjected to 50 copies/mL at 1 month of therapy to 11,500 copies/mL at molecular cloning followed by sequence determination as prethe end of study after 42 months of therapy. was first identified together with two to four of the remaining Alternatively, PCR products were purified with PCR Select III MDR mutations; however, this simultaneous appearance may columns were cloned directly (TA Cloning Kit; InVitrogen, San reflect the limitations of sample availability. HIV-1 isolated Diego). Molecular clones were sequenced as described above.
from patients B and C developed a set of four MDR mutations, HIV-1 RNA quantification. Serum levels of HIV RNA were which excluded the previously reported A62V [5, 9] . However, determined for patients A-E by use of an assay (Amplicor; Roche these HIV-1 populations did acquire the zalcitabine or didanoDiagnostic Systems, Somerville, NJ) following the manufacturer's sine resistance -associated mutation, K65R [19] , and zidovuprotocol. The HIV-1 RNA level for patient F was determined by RT-PCR assay as previously described [5, 10] . dine resistance mutations, K70R and K219E or K219Q [20 -22] / 9d46$$ju44 04-29-98 14:17:02 jinfa UC: J Infect Fatigue, fevers zalcitabine (12), A NOTE. All subjects were men. Treatment modes are expressed as S, simultaneous; C, consecutive; or A, alternating every 2 weeks (zidovudine / didanosine) or every week (zidovudine / zalcitabine). Patient C received 3 months of zidovudine (1200/day) / acyclovir concluding 12 months prior to didanosine monotherapy. Patient F was first reported by Shirasaka et al. (ERS103) [5, 10] . Acid-dissociated p24 levels in serum were determined at end of each therapy. ND Å not detected, ARC Å AIDS-related complex, OI Å opportunistic infection.
Determined at * 40, † 90, and ‡ 38 months of therapy.
(table 2). Other reported zidovudine, didanosine, or zalcitabine Additional mutations developed during therapy. We also asked whether other amino acid substitutions developed in adresistance -associated mutations were not observed together with the MDR mutations, except transiently (patient C).
dition to the five MDR mutations. Although no mutations were observed in common among the 6 patients, S68G was present Zidovudine resistance mutations coexisting with MDR mutations. Patient C is unique among the 6 patients whose HIVin HIV-1 isolated from patients A, B, and C (table 2) . The zalcitabine resistance -associated T69I substitution [23] was 1 developed the MDR mutations, in that Q151M first appeared during didanosine monotherapy ( figure 1C) . A detailed examialso identified in HIV-1 isolated from patients B and C, although these patients were zalcitabine naive. Also noted was nation of the sequence data of HIV-1 from patient C revealed that at 57 months of didanosine monotherapy, Q151M was a substitution K83R in patients B and E and differing amino acid substitutions at codon 162 in patients A, C, and D, to beginning to develop (figure 2). However, when didanosine monotherapy was stopped and zidovudine monotherapy began, tyrosine, tryptophan, and histidine, respectively. We further asked whether other mutations might precede Q151M. This Q151M disappeared while T215Y developed. Other zidovudine resistance mutations (D67N, K70R, and K219Q) plus the zalcioccurred only with HIV-1 isolated from patient C, in which A98S and T200A were observed before Q151M appeared. tabine or didanosine resistance mutation (K65R) also developed (table 2) . These mutations and Q151M coexisted for a MDR versus zidovudine resistance pathways. Finally, we asked whether a certain genetic background might predispose brief period within the HIV-1 population. The Q151M mutation prevailed together with K70R, K219Q, and K65R, possibly by HIV-1 to develop MDR mutations as opposed to T215Y/F or other drug resistance -related mutations. When searching for conveying a greater level of resistance; however, the zidovudine mutations (D67N and T215Y) had disappeared, suggesting residues in common between §2 patients, only Lys at codon 122 and Phe at codon 214 were found among HIV-1 isolated an incompatibility with the MDR mutations. Sequence data on clones generated from two separate time points during this from patients A, B, D, and E (data not shown). However these amino acids are common among published HIV-1 RT setransition in patient C showed that Q151M coexisted with D67N in 8 of 30 clones sequenced and with T215Y in only 1 quences [24] and are indeed present among 13 and 27, respectively, of the other 30 patients in this study who did not develop of 30 clones, although all three never appeared together in any of the clones sequenced (data not shown).
the MDR mutations. Conversely, among the 30 patients whose Patient A62 V75 F77 F116 Q151 K70 K219  K65  K49  S68 T69  R83  W88 A98 K101  S162  D177 T200 I202 Q207 K219 L228 A
NOTE. aa and positions in HIV-1LAI strain are referenced at top. -indicates that aa is same as reference sequence. In patient C, A98S and T200A were identified prior to appearance of MDR mutations. * Mixture. † Substitution from pretherapy aa different from reference sequence.
HIV-1 did not develop MDR, no apparent common genetic isolates from 16 (44%) patients. Isolates from 13 (36%) patients had both M41L and T215Y. One patient's HIV-1 had only a background was identified that might predispose those HIV-1 isolates to develop other drug resistance profiles, such as didanosine resistance-related genotypic change (L74V), and another's had only a zalcitabine resistance-related genotypic change T215Y-mediated zidovudine resistance, as opposed to developing resistance via the MDR pathway.
(T69D). Isolates from 4 (11%) of the 36 patients did not have substitutions associated with nucleoside resistance.
Development of nucleoside resistance-related mutations in HIV-1 that did not show the MDR mutations.
HIV-1 isolated from most of the remaining patients in this study showed the Discussion development of one or more zidovudine-resistance-related mutations (table 3) . Of the 36 patients, 24 (67%) in this study developed
In the present study, we identified a set or subset of amino acid substitutions (A62V, V75I, F77L, F116Y, and Q151M), at least one zidovudine-resistance mutation either alone or in combination with a zalcitabine or didanosine resistance-related which confer MDR on HIV-1, in 6 (17%) of 36 patients, most receiving long-term combination therapy of zidovudine plus mutation(s). The most prevalent zidovudine resistance-related mutations were M41L and T215Y, which were both present in didanosine. In isolates from 2 patients, the Q151M mutation It has been noted that despite long-term chemotherapy with not previously reported to be associated with drug resistance, the following zidovudine, HIV-1 variants carrying all or subsets of the five were also observed: D67G (1), D67E (1), L74I (1), and V75M (1). Zalcitabine mutations do not possess the T215Y/F mutation, which is assoresistance-related mutation, T215C, was observed in 1 reportedly zalcitabinenaive patient. Two other zalcitabine-naive patients showed zalcitabine resisciated with viral resistance to zidovudine [5, 9 -12, 26] . In tance-related mutation T68D.
this study, HIV-1 isolates from none of the 6 patients stably * L74V (HIV-1 from 2 patients) and M184V (HIV-1 from 1 patient) may possessed the Q151M mutation together with the T215Y/F have arisen in response to either zalcitabine or didanosine, since both antivirals were used by these patients.
mutation, in agreement with previous findings [5, 10, 14] . In this respect, it is possible that these two mutations effect an enzymatic constraint toward each other. However, an HIV-1 infectious clone carrying both Q151M and T215Y in an appeared first, while in isolates from 4 other patients, Q151M plus two or more mutations appeared together (figure 1). In 2 HXB2D background actively replicates in vitro [16] , and a recombinant RT with these two mutations have an enzymatic of 3 patients whose HIV-1 developed the MDR mutations reported by Iversen et al. [25] , the Q151M mutation also occurred activity comparable to that of RT wt and is less susceptible to all four ddNTPs tested, ddATP, ddCTP, ddGTP, and AZTTP first, while in the third patient, the Q151M mutation appeared with other mutations. However, Q151M is not always among [14, 15] , suggesting that the two mutations do not impair the replicative ability of HIV-1. It is possible however, that Q151M the first of the MDR mutations to appear: Demeter et al. [26] reported that a patient receiving combination therapy with zidoand T215Y in the background of a clinical isolate may have a different replication profile and may be incompetent. vudine, didanosine, and delavirdine developed A62V, V75I, and F116Y mutations but not the Q151 mutation [26] .
It is also possible that a certain nucleotide or amino acid sequence(s) predisposes HIV-1 to develop the Q151M substituOf note, HIV-1 in 1 of the 6 patients (patient C) developed the Q151M mutation after 57 months of didanosine monothertion and ultimately the rest of the MDR mutations or to develop the T215Y or T215F mutation. However, a comparison of RT apy. This HIV-1 later developed additional MDR mutations while the patient was changing to a combination regimen of sequences of HIV-1 from the 6 patients prior to therapy did not reveal a common background genotype. Similarly, among zidovudine plus lamivudine. Thus, assuming strict treatment compliance in patient C, it appears that the Q151M mutation non-MDR HIV-1 isolates, a common genotype was not identified. It appears that the lack of coexistence of Q151M and can develop following prolonged didanosine monotherapy. While most previously reported cases of HIV-1 developing the T215Y/F among HIV-1 populations within individuals alludes to a model of two distinct pathways of development of resis-Q151M mutation were from patients receiving combination chemotherapy [5, 6, 9 -12, 17, 25] , this particular case may tance to zidovudine, both conveying high-level zidovudine resistance but the MDR pathway also providing resistance to not be so rare. Indeed, Schmit et al. [12] reported an HIV-1 isolate that first developed the Q151M mutation after the patient other dideoxynucleosides. In the present study, all patients (except patient F) had a received zalcitabine monotherapy and then didanosine monotherapy. In addition, preliminary results of another study by mean 1.17 log decrease (range, 0.10 -2.33) in HIV-1 RNA levels within 1 month of therapy ( figure 1) . Initially, CD4 cell Schmit et al. [17] showed the Q151M mutation alone developed in a patient who received stavudine, didanosine, and lamivudine counts also responded favorably (figure 1), but levels were near or below baseline beyond 40 months of therapy. Such loss consecutively. Furthermore, Van Rompay et al. [27] reported that a simian immunodeficiency virus (SIV) isolate developed of clinical benefits generally appeared to coincide with the appearance of the MDR mutations. the Q151M mutation when macaques received prolonged zidovudine treatment [27] . Thus, it appears that MDR may develop
In consideration of studies demonstrating the in vitro phenotypic drug resistance of HIV-1 carrying MDR mutations [5, under combination 
